ELDN today
$2.67-$0.09 (-3.26%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourDescending Triangle
15 minLeaning Bullish
5 minStrong Bullish
Daily trend turns down below $2.11
Key levels
Resistance$2.92
Resistance$2.68
Support$2.38
Support$2.11
Latest news & SEC filings
ProductEledon Pharmaceuticals reports favorable results in Phase 2 BESTOW study
ProductEledon Reports Better Quality of Life for Transplant Recipients on Tegoprubart
All ELDN news →About Eledon Pharmaceuticals
Eledon Pharmaceuticals is a clinical-stage biopharmaceutical company that develops therapies for transplantation and autoimmune diseases. Its lead product candidate, tegoprubart, is an anti-CD40L antibody being studied to prevent organ rejection in transplant patients and to treat conditions such as amyotrophic lateral sclerosis. The company's customers are primarily transplant centers, healthcare providers, and patients. It operates in the United States.
Based on the company's 10-K filed Mar 19, 2026.
Nasdaq · Healthcare
Eledon Pharmaceuticals, Inc. (ELDN)
What Is the Price Target for ELDN?
SEPT Low Target
$12.00
SEPT Mid Target
$12.00
SEPT High Target
$12.00
Analyst Consensus
$12.00
Is ELDN a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ELDN.
Start Free Trial →Is ELDN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$9.19
10
Moat Score
NONE
1/9
Piotroski Score
1.5
Altman Z-Score
What Is Smart Money Doing with ELDN?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ELDN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
21.21%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for ELDN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ELDN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:51:43 | $2.68 | 1,083 | $$3K | SELL |
| 20:39:59 | $2.68 | 1,000 | $$3K | SELL |
| 20:34:40 | $2.69 | 1,000 | $$3K | BUY |
| 20:27:26 | $2.68 | 1,000 | $$3K | SELL |
| 20:21:01 | $2.69 | 1,000 | $$3K | BUY |
5 dark pool trades shown · $$14K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Eledon Pharmaceuticals, Inc. (ELDN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ELDN — frequently asked questions
What is ELDN stock price today?
Eledon Pharmaceuticals, Inc. (ELDN) is at $2.67, down 3.26% (-$0.09) at the Nov 11, 2026 close.
Why is ELDN stock moving today?
Latest ELDN news — Oct 27, 2026: Eledon Pharmaceuticals reports favorable results in Phase 2 BESTOW study · Oct 26, 2026: Eledon Reports Better Quality of Life for Transplant Recipients on Tegoprubart
What is the ELDN price target?
The average analyst price target for ELDN is $12.00, ranging from $12 to $12, based on 1 analysts. Latest: Rodman & Renshaw initiates on Jul 21, 2026.
What do analysts rate ELDN?
Analyst ratings for ELDN: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did ELDN beat earnings?
ELDN last reported on Aug 13, 2026: EPS -$0.27 vs -$0.16 expected — a miss of 70.9%.
Does ELDN pay a dividend?
ELDN does not currently pay a dividend.
What are ELDN support and resistance levels?
Support: $2.38, $2.11, $1.69. Resistance: $2.68, $2.92, $3.22.
What are insiders doing with ELDN?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on ELDN?
Oct 27, 2026: Eledon Pharmaceuticals reports favorable results in Phase 2 BESTOW study · Oct 26, 2026: Eledon Reports Better Quality of Life for Transplant Recipients on Tegoprubart